Mereo BioPharma Group plc (MREO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Denise Vera Scots-Knight Ph.D. | Co-Founder, CEO & Executive Director | 950.95k | -- | 1959 |
| Mr. Charles Edward Sermon | Co-Founder, General Counsel, Business Development & Company Secretary | 668.87k | -- | 1969 |
| Ms. Christine Fox CPA | Chief Financial Officer | 624.45k | -- | 1981 |
| Dr. John P. Richard M.B.A. | Co-Founder & Chief Business Officer | -- | -- | 1957 |
| Dr. John A. Lewicki Ph.D. | Chief Scientific Officer | -- | -- | 1952 |
| Dr. Jackie Parkin | Senior VP & Therapeutic Head | -- | -- | 1958 |
| Ms. Alexandra Hughes-Wilson | Chief of Patient Access & Commercial Planning | -- | -- | 1971 |
| Dr. Suba Krishnan | Senior Vice President of Clinical Development | -- | -- | 1965 |
| Mr. Bo Kara | Senior VP and Head of Pharmaceutical Development & CMC | -- | -- | -- |
Mereo BioPharma Group plc
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 36
Description
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Corporate Governance
Upcoming Events
August 11, 2025 at 12:30 PM UTC - August 18, 2025 at 12:30 PM UTC
Mereo BioPharma Group plc Earnings Date
Recent Events
December 3, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission